A Study in Healthy Participants to Assess the Effect of Darunavir, Emtricitabine, and Tenofovir Alafenamide in the Presence of Cobicistat When Administered as a Fixed Dose Combination (Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide) Compared to the Co-administration of the Separate Agents

PHASE1

Phase

TERMINATED

Status

Enrollment

INDUSTRY

Sponsor class

Stopped COVID-19 pandemic impacted the BE assessment of the trial. The clinical team decided to terminate the trial in order to start a new pivotal BE trial

Conditions

Healthy

Interventions

DRUG: Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide FDC
DRUG: Darunavir
DRUG: Emtricitabine/Tenofovir Alafenamide
DRUG: Cobicistat

Sponsor

Janssen Pharmaceutica N.V., Belgium